Tirzepatide 15mg/30mg Research Peptide

For Research Purposes Only. Not approved for human consumption.

Tirzepatide Research Peptide

Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide. In Phase 3 SURPASS trials, Tirzepatide achieved up to 22.5% weight loss, surpassing Semaglutide's results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (Semaglutide) and triple-mechanism (Retatrutide) approaches.

Research Applications

• Dual incretin (GIP + GLP-1) receptor research
• Advanced metabolic and obesity biology
• Comparative single vs. dual agonist efficacy studies
• Insulin secretion and glucose metabolism research
• Bridge research between Semaglutide and Retatrutide mechanisms

Quality Specifications

• Purity: ≥98% (HPLC verified)
• Compound: Tirzepatide
• Molecular Weight: 4813.5 Da
• Form: Lyophilized powder
• Storage: -20°C, protect from light
• COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: What makes Tirzepatide unique?
A: First dual GIP/GLP-1 agonist ('twincretin') to reach Phase 3. Most metabolic peptides target one receptor. Tirzepatide targets two — establishing dual agonism as superior to single-mechanism approaches.

Q: What were the SURPASS trial results?
A: Tirzepatide achieved up to 22.5% weight loss in Phase 3 trials — exceeding Semaglutide's ~15% and setting the stage for triple agonists like Retatrutide to push further.

Q: How does Tirzepatide fit between Semaglutide and Retatrutide?
A: It is the middle tier: Semaglutide = single agonist (GLP-1 only); Tirzepatide = dual agonist (GLP-1 + GIP); Retatrutide = triple agonist (GLP-1 + GIP + Glucagon). Research often compares all three.